title: Outcomes following second allogeneic haematopoietic transplants using fludarabine-melphalan conditioning.
authors.affiliation: 1] Department of Haematology, St Vincent's Hospital, Darlinghurst, New South Wales, Australia [2] Department of Haematology, Westmead Hospital, Westmead, New South Wales, Australia.
authors.forename: I
authors.identifier: 0000000263750138
authors.initials: I
authors.lastname: Bilmon
authors.affiliation: Australasian Bone Marrow Transplant Recipient Registry, Darlinghurst, New South Wales, Australia.
authors.forename: I
authors.initials: I
authors.lastname: Nivison-Smith
authors.affiliation: Department of Haematology, Westmead Hospital, Westmead, New South Wales, Australia.
authors.forename: M
authors.initials: M
authors.lastname: Hertzberg
authors.affiliation: Department of Haematology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
authors.forename: D
authors.initials: D
authors.lastname: Ritchie
authors.affiliation: Department of Haematology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
authors.forename: M
authors.initials: M
authors.lastname: Greenwood
authors.affiliation: Department of Haematology, Alfred Health, Melbourne, Victoria, Australia.
authors.forename: A
authors.initials: A
authors.lastname: Spencer
authors.affiliation: Department of Haematology, Royal Brisbane Hospital, Herston, Queensland, Australia.
authors.forename: G
authors.initials: G
authors.lastname: Kennedy
authors.affiliation: Department of Haematology, Liverpool Hospital, Liverpool, New South Wales, Australia.
authors.forename: A
authors.initials: A
authors.lastname: Bryant
authors.affiliation: Department of Haematology, St Vincent's Hospital, Darlinghurst, New South Wales, Australia.
authors.forename: J
authors.initials: J
authors.lastname: Moore
mesh_terms: D000328:Adult; D000368:Aged; D064591:Allografts; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage*; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000008:administration & dosage; D019172:Transplantation Conditioning / Q000379:methods; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D055815:Young Adult
chemical_list: D019653:Myeloablative Agonists; D014740:Vidarabine; C024352:fludarabine; D008558:Melphalan